Retinal Vein Occlusion Epidemiology Forecast 2025-2034

Retinal vein occlusion (RVO), a condition with blockage of the retinal veins, can result in decreased blood flow, swelling, and possibly blindness. More than 16 million people suffer from retinal vein occlusion globally. 1 to 4 out of every 1,000 people suffer from central retinal vein occlusion whereas between 6 to 12 out of every 1,000 people suffer from branch retinal vein occlusion.

Retinal Vein Occlusion Epidemiology Forecast Report Coverage

The “Retinal Vein Occlusion Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of retinal vein occlusion. It projects the future incidence and prevalence rates of retinal vein occlusion across various populations. The study covers age, gender, and type as major determinants of the retinal vein occlusion-affected population. The report highlights patterns in the prevalence of retinal vein occlusion over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of retinal vein occlusion in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Retinal Vein Occlusion Disease Overview

Retinal vein occlusion (RVO) is a vascular condition brought on by the blockage of retinal veins, which results in decreased blood flow, fluid leakage, and retinal swelling. Depending on where the blockage is, it is categorized as either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Heart disease, diabetes, high blood pressure, and high cholesterol are common risk factors. Blurred vision, abrupt or gradual vision loss, and retinal hemorrhages which can result in complications like macular edema or neovascularization are some of the symptoms.

Retinal Vein Occlusion: Treatment Overview

To preserve vision, the management of complications such as macular edema and neovascularization is the main goal of treatment for retinal vein occlusion (RVO). Corticosteroids and anti-VEGF injections (such as ranibizumab and aflibercept) aid in lowering retinal swelling and enhancing visual results. In severe cases, laser therapy (also known as grid or panretinal photocoagulation) is used to stop the growth of abnormal blood vessels. To stop progression and recurrence, it is essential to manage underlying conditions such as high blood pressure, diabetes, and high cholesterol. For better blood flow, intraocular surgery or blood thinners may be considered in certain situations.

Epidemiology

The retinal vein occlusion epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for retinal vein occlusion by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for retinal vein occlusion and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Retinal vein occlusion (RVO) is one of the main causes of vision loss. Branch retinal vein occlusion (BRVO) is 4 to 6 times more common than central retinal vein occlusion (CRVO), one of the two primary forms of RVO. Growing older is a basic risk factor for RVO.
• According to population-based studies, the prevalence rates for branch RVO and central RVO are 0.5-2.0% and 0.1-0.2%, respectively. For branch RVO, the estimated 15-year incidence rate is 1.8%, while for central RVO, it is 0.2%.
• A study revealed that RVOs were found in 0.8% of adults in Central India's rural, agrarian, low-income population. Branch retinal vein occlusions were roughly seven times more common than central retinal vein occlusions.

Country-wise Retinal Vein Occlusion Epidemiology

The retinal vein occlusion epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of retinal vein occlusion varies between countries owing to the differences in factors such as high rates of cardiovascular disease, diabetes, hypertension along with aging populations and sedentary lifestyles. In the United States, the overall prevalence of RVO was 0.50%. About 5% to 15% of BRVO eyes develop secondary macular edema within a year, and 50% of these cases result in vision loss.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of retinal vein occlusion based on several factors.
• Retinal Vein Occlusion Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of retinal vein occlusion are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of retinal vein occlusion epidemiology in the 8 major markets?
• What will be the total number of patients with retinal vein occlusion across the 8 major markets during the forecast period?
• What was the country-wise prevalence of retinal vein occlusion in the 8 major markets in the historical period?
• Which country will have the highest number of retinal vein occlusion patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of retinal vein occlusion during the forecast period of 2025-2034?
• What are the currently available treatments for retinal vein occlusion?
• What are the disease risks, signs, symptoms, and unmet needs of retinal vein occlusion?

This product will be delivered within 3-5 business days.